Skye Bioscience (SKYE) Current Assets (2012 - 2026)
Skye Bioscience (SKYE) posted quarterly Current Assets of $18.6 million for Q1 2026, down 70.54% year-over-year from $63.0 million in Q1 2025, and down 31.47% quarter-over-quarter from $27.1 million in Q4 2025.
Skye Bioscience (SKYE) Current Assets (2012 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Current Assets for 15 consecutive years, with $18.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets fell 70.54% year-over-year to $18.6 million; the TTM figure through Mar 2026 stood at $18.6 million (down 70.54% YoY), while the FY2025 annual figure was $27.1 million, down 61.75% from the prior year.
- Current Assets declined to $18.6 million in Q1 2026 per SKYE's latest filing, from $27.1 million in the prior quarter.
- Across five years, Current Assets topped out at $94.6 million in Q1 2024 and bottomed at $1.9 million in Q2 2023.
- Historically, Current Assets has averaged $34.6 million across 5 years, with a median of $18.6 million in 2026.
- Annual changes were most pronounced in 2022 — Current Assets sank 76.53% — and 2024, when it soared 4496.88%.
- Skye Bioscience's Current Assets stood at $8.9 million in 2022, then jumped by 30.27% to $11.7 million in 2023, then jumped by 507.92% to $70.8 million in 2024, then plunged by 61.75% to $27.1 million in 2025, then slumped by 31.47% to $18.6 million in 2026.
- Business Quant data shows SKYE's Current Assets at $18.6 million in Q1 2026, $27.1 million in Q4 2025, and $39.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 1.76 Bn |
| 10 | Skye Bioscience | 10.71 Mn | 10.71 Mn | - | 10.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.57 Mn |
| Dec 31, 2025 | 27.09 Mn |
| Sep 30, 2025 | 39.92 Mn |
| Jun 30, 2025 | 50.58 Mn |
| Mar 31, 2025 | 63.03 Mn |
| Dec 31, 2024 | 70.83 Mn |
| Sep 30, 2024 | 79.81 Mn |
| Jun 30, 2024 | 87.00 Mn |
| Mar 31, 2024 | 94.57 Mn |
| Dec 31, 2023 | 11.65 Mn |
| Sep 30, 2023 | 15.29 Mn |
| Jun 30, 2023 | 1.89 Mn |
| Mar 31, 2023 | 4.45 Mn |
| Dec 31, 2022 | 8.94 Mn |
| Sep 30, 2022 | 2.68 Mn |
| Jun 30, 2022 | 4.77 Mn |
| Mar 31, 2022 | 6.99 Mn |
| Dec 31, 2021 | 9.61 Mn |
| Sep 30, 2021 | 11.43 Mn |
| Jun 30, 2021 | 5.47 Mn |